Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines

European Journal of Cancer

Volumn 46, Issue 15, 2010, Pages 2771-2780

  Das, Chandra M ^a   Zage, Peter E ^a,b   Taylor, Pete ^a   Aguilera, Dolly ^a,c   Wolff, Johannes E A ^a   Lee, Dean ^a   Gopalakrishnan, Vidya ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Etoposide; Histone deacetylase inhibitor; Neuroblastoma; Topoisomerase; Valproic acid

Indexed keywords

ACTIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; HISTONE DEACETYLASE; HISTONE H3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P21; TOPOISOMERASE II BETA; UNCLASSIFIED DRUG; VALPROIC ACID;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; ENZYME INHIBITION; EPIGENETICS; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; TOPOISOMERASE II BETA GENE; UPREGULATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG SYNERGISM; EPIGENOMICS; ETOPOSIDE; HISTONE DEACETYLASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; NEUROBLASTOMA; VALPROIC ACID;

EID: 77957196094     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.05.010     Document Type: Article

References (34)

1. J.M. Maris, M.D. Hogarty, R. Bagatell, and S.L. Cohn Neuroblastoma Lancet 369 2007 2106 2120 (Pubitemid 46935947)
2. G. Leone, M.T. Voso, and S. Sica Therapy related leukemias: susceptibility, prevention and treatment Leuk Lymph 41 2001 255 276 (Pubitemid 32499409)
3. R. Haupt, T.R. Fears, and A. Heise Risk of secondary leukemia after treatment with etoposide (VP-16) for langerhans' cell histiocytosis in Italian and Austrian-German populations Int J Cancer 71 1997 9 13 (Pubitemid 27158402)
4. M. Kuriyama, K. Tsutsui, and Y. Ono Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase IIa Neurol Med Chir (Tokyo) 37 1997 655 662 (Pubitemid 27408378)
5. T. Uesaka, T. Shono, and D. Kuga Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity J Neurooncol 84 2007 119 129 (Pubitemid 47202120)
6. D. Yin, J.M. Ong, and J. Hu Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo Clin Cancer Res 13 2007 1045 1052 (Pubitemid 46340384)
7. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 2006 38 51 (Pubitemid 43054973)
8. L. Ellis, P.W. Atadja, and R.W. Johnstone Epigenetics in cancer: targeting chromatin modifications Mol Cancer Ther 8 2009 1409 1420
9. Q. Yang, P.E. Zage, and D. Kagan Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma Clin Cancer Res 10 2004 8493 8500 (Pubitemid 40053415)
10. M.M. van Noesel, S. van Bezouw, and P.A. Voute Clustering of hypermethylated genes in neuroblastoma Gene Chromosome Cancer 38 2003 226 233 (Pubitemid 37259639)
11. Q. Yang, S. Liu, and Y. Tian Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma Cancer Res 63 2003 6299 6310 (Pubitemid 37255177)
12. Q. Yang, S. Liu, and Y. Tian Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma Cancer Res 64 2004 4531 4538 (Pubitemid 38856925)
13. M. Abe, M. Ohira, and A. Kaneda CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas Cancer Res 65 2005 828 834 (Pubitemid 40216441)
14. D.C. Coffey, M.C. Kutko, and R.D. Glick The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid Cancer Res 61 2001 3591 3594
15. A.J. de Ruijter, S. Kemp, and G. Kramer The novel histone deacetylase inhibitor BL1521 inhibits proliferation and induces apoptosis in neuroblastoma cells Biochem Pharmacol 68 2004 1279 1288 (Pubitemid 39179387)
16. C. Subramanian, A.W. Opipari, V.P. Castle, and R.P. Kwok Histone deacetylase inhibition induces apoptosis in neuroblastoma Cell Cycle 4 2005 1741 1743 (Pubitemid 41827317)
17. M. Gottlicher Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases Ann Hematol 83 2004 S91 S92
18. N. Gurvich, O.M. Tsygankova, J.L. Meinkoth, and P.S. Klein Histone deacetylase is a target of valproic acid-mediated cellular differentiation Cancer Res 64 2004 1079 1086 (Pubitemid 38176913)
19. O. Witt, L. Schweigerer, and P.H. Driever Valproic acid treatment of glioblastoma multiforme in a child Pediatr Blood Cancer 43 2004 181 (Pubitemid 38891170)
20. P.H. Driever, M.M. Knüpfer, J. Cinatl, and J.E.A. Wolff Valproic acid for the treatment of pediatric malignant glioma Klin Pediatr 211 1999 323 328 (Pubitemid 29364777)
21. J. Cinatl Jr, R. Kotchetkov, and R. Blaheta Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha Int J Oncol 20 2002 97 106
22. S.E. Furchert, C. Lanvers-Kaminsky, and H. Juurgens Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood Int J Cancer 120 2007 1787 1794 (Pubitemid 46399367)
23. J.L. Biedler, L. Helson, and B.A. Spengler Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture Cancer Res 33 1973 2643 2652
24. C.P. Reynolds, M.M. Tomayko, and L. Donner Biological classification of cell lines derived from human extra-cranial neural tumors Prog Clin Biol Res 2 1988 291 306
25. C.M. Das, D. Aguilera, and H. Vasquez Valproic acid induces p21 and topoisomerase-II (α/β) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines J Neurooncol 85 2007 159 170 (Pubitemid 47629397)
26. D.G. Aguilera, C.M. Das, and N.D. Sinnappah-Kang Reactivation of death receptor 4 (DR4) expression sensitizes medulloblastoma cell lines to TRAIL J Neurooncol 93 2009 303 318
27. S.C. Tsai, N. Valkov, and W.M. Yang Histone deacetylase interacts directly with DNA topoisomerase II Nat Genet 26 2000 349 353
28. E.U. Kurz, S.E. Wilson, and K.B. Leader The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines Mol Cancer Ther 1 2001 121 131
29. D.C. Marchion, E. Bicaku, and A.I. Daud Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid J Cell Biochem 92 2004 223 237
30. N. Keshelava, E. Davicioni, and Z. Wan Histone deacetylase 1 gene expression and sensitization of multi-drug resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide J Natl Cancer Inst 99 2007 1107 1119 (Pubitemid 47241395)
31. A. Coss, M. Tosetto, and E.J. Fox Increased topoisomerase II alpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis Cancer Lett 276 2009 228 238
32. C.M. Whitacre, E. Zborowska, and N.H. Gordon Topotecan increases topoisomerase IIa levels and sensitivity to treatment with etoposide in schedule-dependent process Cancer Res 57 1997 1425 1428 (Pubitemid 27175554)
33. D.C. Marchion, E. Bicaku, and J.G. Turner Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase II beta Clin Cancer Res 11 2005 8467 8475 (Pubitemid 41746962)
34. C.N. Lok, A.J. Lang, and S.E. Mirski Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites Biochem J 368 2002 741 751